JSMC
LCTX icon

Jess S. Morgan & Co’s Lineage Cell Therapeutics LCTX Stock Holding History

Jess S. Morgan & Co’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-20,000
Closed -$32K – 39
2022
Q2 		$32K Buy
20,000
+5,000
+33% +$6.59K 0.03% 37
2022
Q1 		$23K Hold
15,000
– – 0.02% 43
2021
Q4 		$37K Hold
15,000
– – 0.02% 45
2021
Q3 		$38K Buy
+15,000
New +$38.5K 0.03% 41

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Jess S. Morgan & Co's LCTX Position: Q3 2022 in Review

Jess S. Morgan & Co sold out of Lineage Cell Therapeutics (LCTX) in Q3 2022, closing a stake of 20,000 shares — an estimated $32K sold.

Jess S. Morgan & Co first reported a position in LCTX in Q3 2021 and held it in 4 quarters. The position peaked at $38K in Q3 2021. 105 funds tracked by Wall St. Rank hold LCTX as of Q3 2022.

  • Jess S. Morgan & Co reported no remaining Lineage Cell Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Jess S. Morgan & Co sold 20,000 Lineage Cell Therapeutics shares in Q3 2022, an estimated $32K.
  • Jess S. Morgan & Co first reported a position in Lineage Cell Therapeutics in Q3 2021 and held it in 4 quarters.
  • Jess S. Morgan & Co's Lineage Cell Therapeutics position peaked at $38K in Q3 2021.
  • 105 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2022.

Based on Jess S. Morgan & Co's 13F filing for Q3 2022, filed 21 Oct 2022.